| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/03/2023 | 240.91% | RBC Capital | $4 → $3 | Maintains | Outperform |
| 08/07/2023 | 354.55% | Morgan Stanley | $5 → $4 | Maintains | Equal-Weight |
| 08/03/2023 | 695.45% | Piper Sandler | $8 → $7 | Maintains | Overweight |
| 08/03/2023 | 354.55% | RBC Capital | $5 → $4 | Maintains | Outperform |
| 08/03/2023 | 1036.36% | HC Wainwright & Co. | → $10 | Reiterates | Buy → Buy |
| 07/26/2023 | 354.55% | Wedbush | $7 → $4 | Maintains | Neutral |
| 07/26/2023 | 1036.36% | HC Wainwright & Co. | → $10 | Reiterates | Buy → Buy |
| 07/18/2023 | 1036.36% | HC Wainwright & Co. | → $10 | Reiterates | Buy → Buy |
| 05/05/2023 | 468.18% | RBC Capital | $6 → $5 | Maintains | Outperform |
| 05/05/2023 | 1036.36% | HC Wainwright & Co. | $16 → $10 | Maintains | Buy |
| 05/05/2023 | 1036.36% | Baird | $14 → $10 | Maintains | Outperform |
| 04/19/2023 | 1718.18% | HC Wainwright & Co. | → $16 | Reiterates | → Buy |
| 02/22/2023 | 1718.18% | HC Wainwright & Co. | → $16 | Maintains | Buy |
| 02/16/2023 | 1718.18% | HC Wainwright & Co. | → $16 | Reiterates | → Buy |
| 01/27/2023 | 468.18% | Morgan Stanley | $7 → $5 | Maintains | Equal-Weight |
| 01/19/2023 | 809.09% | Piper Sandler | → $8 | Initiates Coverage On | → Overweight |
| 01/10/2023 | 1718.18% | HC Wainwright & Co. | $18 → $16 | Maintains | Buy |
| 01/10/2023 | 468.18% | SVB Leerink | $6 → $5 | Maintains | Market Perform |
| 11/04/2022 | 1036.36% | RBC Capital | $7 → $10 | Upgrades | Sector Perform → Outperform |
| 11/04/2022 | 581.82% | SVB Leerink | $5 → $6 | Maintains | Market Perform |
| 09/09/2022 | 695.45% | Morgan Stanley | $10 → $7 | Maintains | Equal-Weight |
| 08/05/2022 | 1945.45% | HC Wainwright & Co. | $21 → $18 | Maintains | Buy |
| 08/05/2022 | 1490.91% | Baird | $17 → $14 | Maintains | Outperform |
| 08/05/2022 | 809.09% | Barclays | $14 → $8 | Maintains | Overweight |
| 05/05/2022 | 468.18% | SVB Leerink | $6 → $5 | Maintains | Market Perform |
| 03/18/2022 | 2400% | HC Wainwright & Co. | $23 → $22 | Maintains | Buy |
| 03/08/2022 | 809.09% | RBC Capital | $12 → $8 | Maintains | Sector Perform |
| 03/02/2022 | 581.82% | SVB Leerink | $8 → $6 | Maintains | Market Perform |
| 02/09/2022 | 809.09% | JP Morgan | → $8 | Upgrades | Underweight → Neutral |
| 01/10/2022 | 809.09% | SVB Leerink | $6 → $8 | Maintains | Market Perform |
| 12/09/2021 | 922.73% | RBC Capital | $8 → $9 | Maintains | Sector Perform |
| 11/19/2021 | 1036.36% | Morgan Stanley | $27 → $10 | Downgrades | Overweight → Equal-Weight |
| 10/12/2021 | 2968.18% | Morgan Stanley | $29 → $27 | Maintains | Overweight |
| 08/06/2021 | 2854.55% | HC Wainwright & Co. | $49 → $26 | Maintains | Buy |
| 08/06/2021 | 581.82% | SVB Leerink | → $6 | Downgrades | Outperform → Market Perform |
| 08/06/2021 | 809.09% | RBC Capital | $17 → $8 | Downgrades | Outperform → Sector Perform |
| 08/06/2021 | — | JP Morgan | Downgrades | Overweight → Underweight | |
| 05/03/2021 | 1604.55% | SVB Leerink | $22 → $15 | Maintains | Outperform |
| 02/11/2021 | 2400% | SVB Leerink | $25 → $22 | Maintains | Outperform |
| 01/12/2021 | 2740.91% | SVB Leerink | $29 → $25 | Maintains | Outperform |
| 11/03/2020 | 3536.36% | Morgan Stanley | $34 → $32 | Maintains | Overweight |
| 11/03/2020 | 3081.82% | SVB Leerink | $30 → $28 | Maintains | Outperform |
| 08/04/2020 | 3309.09% | SVB Leerink | $31 → $30 | Maintains | Outperform |
| 07/02/2020 | 3763.64% | Morgan Stanley | → $34 | Initiates Coverage On | → Overweight |
| 06/23/2020 | 2854.55% | Wedbush | $25 → $26 | Maintains | Neutral |
| 06/23/2020 | 4559.09% | HC Wainwright & Co. | $40 → $41 | Maintains | Buy |
| 05/06/2020 | 4445.45% | HC Wainwright & Co. | $43 → $40 | Maintains | Buy |
| 05/05/2020 | 3195.45% | SVB Leerink | $30 → $29 | Maintains | Outperform |
| 03/04/2020 | 3309.09% | Barclays | → $30 | Initiates Coverage On | → Overweight |
| 03/02/2020 | 4786.36% | HC Wainwright & Co. | $40 → $43 | Maintains | Buy |
| 01/17/2020 | — | Wedbush | Downgrades | Outperform → Neutral | |
| 01/14/2020 | 4104.55% | HC Wainwright & Co. | $36 → $37 | Reiterates | → Buy |
| 11/05/2019 | 1945.45% | Canaccord Genuity | $15 → $18 | Maintains | Buy |
| 11/05/2019 | 3990.91% | HC Wainwright & Co. | $32 → $36 | Maintains | Buy |
| 07/23/2019 | 1718.18% | JP Morgan | $8 → $16 | Upgrades | Neutral → Overweight |
| 03/01/2019 | 695.45% | JP Morgan | $21 → $7 | Downgrades | Overweight → Neutral |
| 02/27/2019 | 581.82% | Wedbush | $14 → $6 | Maintains | Outperform |
| 02/27/2019 | — | B of A Securities | Downgrades | Neutral → Underperform | |
| 01/03/2019 | — | B of A Securities | Upgrades | Underperform → Neutral | |
| 11/09/2018 | — | Wedbush | Upgrades | Neutral → Outperform |
What is the target price for Karyopharm Therapeutics (KPTI)?
The latest price target for Karyopharm Therapeutics (NASDAQ: KPTI) was reported by RBC Capital on November 3, 2023. The analyst firm set a price target for $3.00 expecting KPTI to rise to within 12 months (a possible 240.91% upside). 20 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Karyopharm Therapeutics (KPTI)?
The latest analyst rating for Karyopharm Therapeutics (NASDAQ: KPTI) was provided by RBC Capital, and Karyopharm Therapeutics maintained their outperform rating.
When is the next analyst rating going to be posted or updated for Karyopharm Therapeutics (KPTI)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Karyopharm Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Karyopharm Therapeutics was filed on November 3, 2023 so you should expect the next rating to be made available sometime around November 3, 2024.
Is the Analyst Rating Karyopharm Therapeutics (KPTI) correct?
While ratings are subjective and will change, the latest Karyopharm Therapeutics (KPTI) rating was a maintained with a price target of $4.00 to $3.00. The current price Karyopharm Therapeutics (KPTI) is trading at is $0.88, which is out of the analyst's predicted range.